Rheumatoid arthritis

FILE - In this July 6, 2020 file photo, a health care worker administers a COVID-19 test at a site sponsored by Community Heath of South Florida at the Martin Luther King, Jr. Clinica Campesina Health Center in Homestead, Fla. A drug company says on Friday, Sept. 18, that a medicine it sells to tamp down inflammation has helped prevent the need for breathing machines in hospitalized COVID-19 patients in the first large study that primarily enrolled minorities. (AP Photo/Lynne Sladky, File)
September 18, 2020 - 11:37 am
A drug company said Friday that a medicine it sells to tamp down inflammation has helped prevent the need for breathing machines in hospitalized COVID-19 patients in the first large study that primarily enrolled Hispanics and Blacks. Switzerland-based Roche reported the results for tocilizumab,...
Read More
This undated electron microscope image made available by the U.S. National Institutes of Health in February 2020 shows the virus that causes COVID-19. The sample was isolated from a patient in the U.S. (NIAID-RML via AP)
March 19, 2020 - 4:51 pm
President Donald Trump focused attention on possible treatments for the new coronavirus on Thursday, citing potential use of a drug long used to treat malaria and some other approaches still in testing. At a White House news conference, Trump and Food and Drug Administration Commissioner Dr...
Read More
FILE - In this July 16, 2012 file photo, Johnson & Johnson products are displayed in Orlando, Fla. Johnson & Johnson reports earnings, Tuesday, Oct. 17, 2017. (AP Photo/John Raoux, File)
October 17, 2017 - 8:39 am
Higher spending across the board drove Johnson & Johnson's third-quarter profit down 12 percent, despite a big sales jump fueled by recent acquisitions, hot new cancer drugs and strong sales of other key medicines. However, the health care giant easily topped Wall Street expectations. With...
Read More
King Michael Odunayo Ajayi, right, of Nigeria's Osun state, is escorted by Jim Byrne, New York Stock Exchange head of U.S. listings, as he visits the trading floor of the NYSE, Monday, April 17, 2017. (AP Photo/Richard Drew)
April 17, 2017 - 4:28 pm
NEW YORK (AP) — U.S. stocks bounced back from recent losses Monday after the Chinese government said that country's economy grew at a slightly faster pace in the first quarter. Banks jumped as interest rates recovered. After losses in three of the last four weeks, stocks had their best day in more...
Read More
King Michael Odunayo Ajayi, right, of Nigeria's Osun state, is escorted by Jim Byrne, New York Stock Exchange head of U.S. listings, as he visits the trading floor of the NYSE, Monday, April 17, 2017. (AP Photo/Richard Drew)
April 17, 2017 - 11:27 am
NEW YORK (AP) — U.S. stocks are starting higher Monday as investors get back to trading after the Easter holiday weekend. Technology companies are making some of the largest gains and industrial and consumer-focused companies are also rising after the Chinese government said that country's economy...
Read More
FILE - This Thursday, June 30, 2011, file photo shows a sign in front of the Eli Lilly and Company corporate headquarters in Indianapolis. On Friday, April 14, 2017, Eli Lilly said U.S. regulators have rejected its much-anticipated pill for the immune disorder rheumatoid arthritis, the drugmaker's second drug development setback since November 2016. (AP Photo/Darron Cummings, File)
April 14, 2017 - 12:34 pm
Eli Lilly said U.S. regulators have rejected its much-anticipated pill for the immune disorder rheumatoid arthritis, the drugmaker's second drug development setback since November. The Food and Drug Administration said in a letter to the company that it needed more information about the drug's...
Read More
April 14, 2017 - 11:27 am
Eli Lilly says U.S. regulators have rejected its much-anticipated pill for the immune disorder rheumatoid arthritis, the drugmaker's second drug development setback since November. The Food and Drug Administration said in a letter to the company that additional data from patient tests would be...
Read More